GlassScriptPhysician profile
Meredith S Quarles
NPI 1104225101
$10,834.47
in general payments reported to CMS, 2019-2025
37 companies · $1,213 in 2025
The $1,213 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,950 · 2022: $2,429 · 2023: $2,386 · 2024: $1,857 · 2025: $1,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,455.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,059.69 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,893.45 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,243.21 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $941.75 | 2021-2025 | |
| Lilly USA, LLC | $846.26 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $530.28 | 2021-2023 | Xarelto |
| Amgen INC. | $425.37 | 2021-2025 | Otezla, Repatha, Evenity |
| Abbott Laboratories | $413.46 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.42 | 2021-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $294.57 | 2022 | |
| Glaxosmithkline, LLC. | $258.63 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $247.75 | 2021 | |
| Esperion Therapeutics, INC. | $184.27 | 2021-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $133.88 | 2021-2022 | |
| Exact Sciences Corporation | $127.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Quarles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.